Skip to main content
Figure 4 | BMC Biotechnology

Figure 4

From: Killing cancer cells by targeted drug-carrying phage nanomedicines

Figure 4

analysis of the Cathepsin-B released material. A. The crude cathepsin-B released material from re-suspended, PEG-precipitated, cathepsin-B treated, doxorubicin-carrying fUSE5-ZZ-(p8)DFK phages was analysed using a gradient of acetonitrile in water on a Waters HPLC machine (RP; C-18 column) following the doxorubicin specific emission wavelength 480 nm. Cathepsin-B released material eluted at 24–25 minutes post injection. B. The crude cathepsin-B released material was analyzed by MALDI TOF MS. The theoretical mass of the aspartate-doxorubicin (shown in the insert) was observed by the mass spectrometry Analysis as a major peak 656.04 (marked by arrow – corresponding to the weight of aspartate-doxorubicin.

Back to article page